학술논문

Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
Document Type
article
Source
Nature chemical biology. 17(1)
Subject
QCRG Structural Biology Consortium
Vero Cells
Animals
Humans
Peptide Library
Antibodies
Viral
Binding Sites
Antibody
Cryoelectron Microscopy
Protein Binding
Models
Molecular
Protein Interaction Domains and Motifs
Single-Chain Antibodies
Antibodies
Neutralizing
HEK293 Cells
Spike Glycoprotein
Coronavirus
Protein Conformation
alpha-Helical
Protein Conformation
beta-Strand
Chlorocebus aethiops
Angiotensin-Converting Enzyme 2
SARS-CoV-2
Biochemistry & Molecular Biology
Medicinal and Biomolecular Chemistry
Biochemistry and Cell Biology
Language
Abstract
Neutralizing agents against SARS-CoV-2 are urgently needed for the treatment and prophylaxis of COVID-19. Here, we present a strategy to rapidly identify and assemble synthetic human variable heavy (VH) domains toward neutralizing epitopes. We constructed a VH-phage library and targeted the angiotensin-converting enzyme 2 (ACE2) binding interface of the SARS-CoV-2 Spike receptor-binding domain (Spike-RBD). Using a masked selection approach, we identified VH binders to two non-overlapping epitopes and further assembled these into multivalent and bi-paratopic formats. These VH constructs showed increased affinity to Spike (up to 600-fold) and neutralization potency (up to 1,400-fold) on pseudotyped SARS-CoV-2 virus when compared to standalone VH domains. The most potent binder, a trivalent VH, neutralized authentic SARS-CoV-2 with a half-maximal inhibitory concentration (IC50) of 4.0 nM (180 ng ml-1). A cryo-EM structure of the trivalent VH bound to Spike shows each VH domain engaging an RBD at the ACE2 binding site, confirming our original design strategy.